Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
AstraZeneca
AstraZeneca
Novartis
Stanford University
Sermonix Pharmaceuticals Inc.
Novartis
MedSIR
Novartis
Canadian Cancer Trials Group
Carrick Therapeutics Limited
Hoffmann-La Roche
Stemline Therapeutics, Inc.
Lund University Hospital
Pfizer
MedSIR
Duke University
Menarini Group
Boehringer Ingelheim
Institute of Cancer Research, United Kingdom
Massachusetts General Hospital
Memorial Sloan Kettering Cancer Center
University of California, San Francisco
Emory University
Novartis
Georgetown University
MedSIR
MedSIR
Columbia University
Queen Mary University of London
Eli Lilly and Company
Vanderbilt-Ingram Cancer Center
Genor Biopharma Co., Ltd.
Spanish Breast Cancer Research Group
University of Pittsburgh
Eli Lilly and Company
Novartis
AstraZeneca
University Hospital, Gasthuisberg
Washington University School of Medicine
Merus B.V.
ETOP IBCSG Partners Foundation
Novartis
National Cancer Institute (NCI)
Jiangsu HengRui Medicine Co., Ltd.
Kashiv BioSciences, LLC
MedSIR
GBG Forschungs GmbH
Novartis